NFKB1 and Miyoshi myopathy: Moreover, preclinical studies have provided strong evidence that IGF-I protects against various standard and novel anti-MM agents, such as dexamethasone, Apo2/TRAIL, ABT-737, NF-κB inhibitor, and bortezomib [107–110].